A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway

Brain Research

Volumn 1203, Issue , 2008, Pages 160-169

  Gomes, Margarete Zanardo ^a   Raisman Vozari, Rita ^b,c,d   Del Bel, Elaine A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Cingulate cortex; Dopamine; Globus pallidus; l NOARG; Neuronal nitric oxide synthase; Parkinson's disease; Substantia nigra

Indexed keywords

N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL DENSITY; CELL LOSS; CINGULATE GYRUS; CONTROLLED STUDY; DRUG EFFECT; GLOBUS PALLIDUS; MALE; NERVE CELL; NIGRONEOSTRIATAL SYSTEM; NITRERGIC NERVE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; CELL COUNT; CORPUS STRIATUM; DRUG INTERACTIONS; ENZYME INHIBITORS; MALE; NEURAL PATHWAYS; NITRIC OXIDE SYNTHASE TYPE I; NITROARGININE; OXIDOPAMINE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 40949097682     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.01.088     Document Type: Article

References (73)

1. Agid Y. Parkinson's disease: pathophysiology. Lancet 337 (1991) 1321-1324
2. Anaya-Martinez V., Martinez-Marcos A., Martinez-Fong D., Aceves J., and Erlij D. Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: implications for abnormal motor behavior. Neuroscience 143 (2006) 477-486
3. Antunes F., Nunes C., Laranjinha J., and Cadenas E. Redox interactions of nitric oxide with dopamine and its derivatives. Toxicology 208 (2005) 207-212
4. Barthwal M.K., Srivastava N., and Dikshit M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat. Redox Rep. 6 (2001) 297-302
5. Benavides-Piccione R., and DeFelipe J. Different populations of tyrosine-hydroxylase-immunoreactive neurons defined by differential expression of nitric oxide synthase in the human temporal cortex. Cereb. Cortex 13 (2003) 297-307
6. Blandini F., Levandis G., Bazzini E., Nappi G., and Armentero M.T. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur. J. Neurosci. 25 (2007) 397-405
7. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 (2001) 135-172
8. Bredt D.S., and Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. 87 (1990) 682-685
9. Bredt D.S., Hwang P.M., and Snyder S.H. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 347 (1990) 768-770
10. Carreau A., Duval D., Poignet H., Scatton B., Vige X., and Nowicki J.P. Neuroprotective efficacy of N omega-nitro-l-arginine after focal cerebral ischemia in the mouse and inhibition of cortical nitric oxide synthase. Eur. J. Pharmacology 256 (1994) 241-249
11. Centonze D., Bracci E., Pisani A., Gubellini P., Bernardi G., and Calabresi P. Activation of dopamine D1-like receptor excites LTS interneurons of the striatum. Eur. J. Neurosci. 15 (2002) 2049-2052
12. Chalimoniuk M., Langfort J., Lukacova N., and Marsala J. Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice. Biochem. Biophys. Res. Commun. 324 (2004) 118-126
13. Chalimoniuk M., Lukacova N., Marsala J., and Langfort J. Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neuroscience 141 (2006) 1033-1046
14. Dawson T.M., Dawson V.L., and Snyder S.H. Molecular mechanisms of nitric oxide actions in the brain. Ann. N.Y. Acad. Sci. 738 (1994) 76-85
15. De Oliveira C.L., Del Bel E.A., and Guimarães F.S. Effects of l-NOARG on plus-maze performance in rats. Pharmacol. Biochem. Behav. 56 (1997) 55-59
16. Debeir T., Ginestet L., Francois C., Laurens S., Martel J.C., Chopin P., Marien M., Colpaert F., and Raisman-Vozari R. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Exp Neurol. 193 (2005) 444-454
17. Del Bel E.A., and Guimarães F.S. Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice. Psychopharmacology (Berl) 147 4 (2000) 356-361
18. Del Bel E.A., Souza A.S., Guimaraes F.S., da Silva C.A., and Nucci da Silva L.P. Motor effects of acute and chronic inhibition of nitric oxide synthesis in mice. Psychopharmacology (Berl) 161 (2002) 32-37
19. Del Bel E.A., Guimarães F.S., Bermúdez-Echeverry M., Gomes M.Z., Schiaveto-de-Souza A., Padovan-Neto F.E., Tumas V., Barion-Cavalcanti A.P., Lazzarini M., Nucci-da-Silva L.P., and de Paula-Souza D. Role of nitric oxide on motor behavior. Cell Mol. Neurobiol. 25 (2005) 371-392
20. Deutch A.Y., Goldstein M., Baldino Jr. F., and Roth R.H. Telencephalic projections of the A8 dopamine cell group. Ann. N. Y. Acad. Sci. 537 (1988) 27-50
21. de Vente J., Markerink-van Ittersum M., van Abeelen J., Emson P.C., Axer H., and Steinbusch H.W. NO-mediated cGMP synthesis in cholinergic neurons in the rat forebrain: effects of lesioning dopaminergic or serotonergic pathways on nNOS and cGMP synthesis. Eur. J. Neurosci. 12 (2000) 507-519
22. Di Matteo V., Benigno A., Pierucci M., Giuliano D.A., Crescimanno G., Esposito E., and Di Giovanni G. 7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study. Ann. N. Y. Acad. Sci. 1089 (2006) 462-471
23. Douhou A., Debeir T., Murer M.G., Do L., Dufour N., Blanchard V., Moussaoui S., Bohme G.A., Agid Y., and Raisman-Vozari R. Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice. Exp. Neurol. 176 (2002) 247-253
24. Dwyer M.A., Bredt D.S., and Snyder S.H. Nitric oxide synthase: irreversible inhibition by l-NG-nitroarginine in brain in vitro and in vivo. Biochem. Biophys. Res. Commun. 176 (1991) 1136-1141
25. Fahn S., and Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32 (1992) 804-812
26. Fallon J.H., and Moore R.Y. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol. 180 (1978) 545-580
27. Forstermann U., Schmidt H.H., Pollock J.S., Sheng H., Mitchell J.A., Warner T.D., Nakane M., and Murad F. Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem. Pharmacol. 42 (1991) 1849-1857
28. Freeman A., Ciliax B., Bakay R., Daley J., Miller R.D., Keating G., Levey A., and Rye D. Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models. Ann. Neurol. 50 (2001) 321-329
29. Fujiyama F., and Masuko S. Association of dopaminergic terminals and neurons releasing nitric oxide in the rat striatum: an electron microscopic study using NADPH-diaphorase histochemistry and tyrosine hydroxylase immunohistochemistry. Brain Res. Bull. 40 (1996) 121-127
30. Gauthier J., Parent M., Levesque M., and Parent A. The axonal arborisation of single nigrostriatal neurons in rats. Brain Res. 834 (1999) 228-232
31. Gomes M.Z., and Del Bel E.A. Effects of electrolytic and 6-hydroxydopamine lesions of rat nigrostriatal pathway on nitric oxide synthase and nicotinamide adenine dinucleotide phosphate diaphorase. Brain Res. Bull. 62 (2003) 107-115
32. Gomez-Urquijo S.M., Hökfelt T., Ubink R., Lubec G., and Herrera-Marschitz M. Neurocircuitries of the basal ganglia studied in organotypic cultures: focus on tyrosine hydroxylase, nitric oxide synthase and neuropeptide immunocytochemistry. Neuroscience 94 4 (1999) 1133-1151
33. Haber S.N., and Fudge J.L. The primate substantia nigra and VTA: integrative circuitry and function. Crit. Rev. Neurobiol. 11 (1997) 323-342
34. Hanrott K., Gudmunsen L., O'Neill M.J., and Wonnacott S. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 281 (2006) 5373-5382
35. Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R.T., and Beal M.F. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2 (1996) 1017-1021
36. Henze C., Earl C., Sautter J., Schmidt N., Themann C., Hartmann A., and Oertel W.H. Reactive oxidative and nitrogen species in the nigrostriatal system following striatal 6-hydroxydopamine lesion in rats. Brain Res. 1052 (2005) 97-104
37. Herbison A.E., Simonian S.X., Norris P.J., and Emson P.C. Relationship of neuronal nitric oxide synthase immunoreactivity to GnRH neurons in the ovariectomized and intact female rat. J. Neuroendocrinol. 8 (1996) 73-82
38. Hu M.T., Scherfler C., Khan N.L., Hajnal J.V., Lees A.J., Quinn N., Wood N.W., and Brooks D.J. Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease. Mov. Disord. 21 (2006) 299-305
39. Hutchinson M., and Raff U. Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra. J. Neurol. Neurosurg. Psychiatry. 67 (1999) 815-818
40. Hutchinson M., Raff U., and Lebedev S. MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIRRIM). Neuroimage 20 (2003) 1899-1902
41. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (2003) 26-38
42. Kavya R., Saluja R., Singh S., and Dikshit M. Nitric oxide synthase regulation and diversity: implications in Parkinson's disease. Nitric Oxide 15 (2006) 280-294
43. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
44. Kiss J.P., Zsilla G., and Vizi E.S. Inhibitory effect of nitric oxide on dopamine transporters: interneuronal communication without receptors. Neurochem. Int. 45 (2004) 485-489
45. Klatt P., Heinzel B., John M., Kastner M., Bohme E., and Mayer B. Ca2+/calmodulin-dependent cytochrome c reductase activity of brain nitric oxide synthase. J. Biol. Chem. 267 (1992) 11374-11378
46. Lonart G., and Johnson K.M. Inhibitory effects of nitric oxide on the uptake of [3H]dopamine and [3H]glutamate by striatal synaptosomes. J. Neurochem. 63 (1994) 2108-2117
47. Marras R.A., Martins A.P., Del Bel E.A., and Guimaraes F.S. l-NOARG, an inhibitor of nitric oxide synthase, induces catalepsy in mice. Neuroreport 7 (1995) 158-160
48. Morton A.J., Nicholson L.F.B., and Faull R.L.M. Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington's disease. Neuroscience 53 (1993) 159-168
49. Morris B.J., Simpson C.S., Mundell S., Maceachern K., Johnston H.M., and Nolan A.M. Dynamic changes in NADPH-diaphorase staining reflect activity of nitric oxide synthase: evidence for a dopaminergic regulation of striatal nitric oxide release. Neuropharmacology 36 (1997) 1589-1599
50. Muramatsu Y., Kurosaki R., Mikami T., Michimata M., Matsubara M., Imai Y., Kato H., Itoyama Y., and Araki T. Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice. Metab. Brain Dis. 17 (2002) 169-182
51. Olds M.E., Jacques D.B., and Kopyov O. Relation between rotation in the 6-OHDA lesioned rat and dopamine loss in striatal and substantia nigra sub regions. Synapse 59 (2006) 532-544
52. Palumbo A., Napolitano A., Carraturo A., Russo G.L., and d'Ischia M. Oxidative conversion of 6-nitrocatecholamines to nitrosating products: a possible contributory factor in nitric oxide and catecholamine neurotoxicity associated with oxidative stress and acidosis. Chem. Res. Toxicol. 14 (2001) 1296-1305
53. Pavon N., Martin A.B., Mendialdua A., and Moratalla R. ERK phosphorilation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry. 59 (2006) 64-74
54. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. Fourth edition (1998), Academic Press, San Diego
55. Pogun S., Baumann M.H., and Kuhar M.J. Nitric oxide inhibits [3H]dopamine uptake. Brain Res. 641 (1994) 83-91
56. Prensa L., and Parent A. The nigrostriatal pathway in the rat: a single-axon study of the relationship between dorsal and ventral tier nigral neurons and the striosome/matrix striatal compartments. J. Neurosci. 21 (2001) 7247-7260
57. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., and Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67 (1995) 631-647
58. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., and Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. 93 (1996) 4565-4571
59. Riobo N.A., Schopfer F.J., Boveris A.D., Cadenas E., and Poderoso J.J. The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease. Free Radic. Biol. Med. 32 (2002) 115-121
60. Sancesario G., Giorgi M., D'Angelo V., Modica A., Martorana A., Morello M., Bengtson C.P., and Bernardi G. Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur.J.Neurosci. 20 (2004) 989-1000
61. Sauer H., and Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 (1994) 401-415
62. Schulz J.B., Matthews R.T., Muqit M.M., Browne S.E., and Beal M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64 (1995) 936-939
63. Sergeeva O.A., Doreulee N., Chepkova A.N., Kazmierczak T., and Haas H.L. Long-term depression of cortico-striatal synaptic transmission by DHPG depends on endocannabinoid release and nitric oxide synthesis. Eur. J. Neurosci. 26 (2007) 1889-1894
64. Singh S., Das T., Ravindran A., Chaturvedi R.K., Shukla Y., Agarwal A.K., and Dikshit M. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease. Redox Rep. 10 (2005) 103-109
65. Smith M.P., and Cass W.A. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience 144 (2006) 1057-1066
66. Solis O., Limon D.I., Flores-Hernandez J., and Flores G. Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson's disease. Synapse 61 (2007) 450-458
67. Traystman R.J., Moore L.E., Helfaer M.A., Davis S., Banasiak K., Williams M., and Hurn P.D. Nitro-l-arginine analogues. Dose- and time-related nitric oxide synthase inhibition in brain. Stroke 26 (1995) 864-869
68. Van den Munckhof P., Gilbert F., Chamberland M., Levesque D., and Drouin J. Striatal neuroadaptation and rescue of locomotor deficit by l-dopa in aphakia mice, a model of Parkinson's disease. J. Neurochem. 96 (2006) 160-170
69. Volz T.J., and Schenk J.O. l-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism. Synapse 54 (2004) 173-182
70. Watanabe, Y., Hiroyuki, K., Araki, T. Protective action of neuronal nitric oxide synthase inhibitor in the mouse model of Parkinson's disease. Met. Brain Dis. Nov., 21 (Electronic publication).
71. West A.R., and Galloway M.P. Nitric oxide and potassium chloride-facilitated striatal dopamine efflux in vivo: role of calcium-dependent release mechanisms. Neurochem. Int. 33 (1998) 493-501
72. West A.R., Galloway M.P., and Grace A.A. Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signalling mechanisms. Synapse 44 (2002) 227-245
73. Winkler C., Kirik D., Bjorklund A., and Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10 (2002) 165-186